Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Stage I Prostate Adenocarcinoma × Raloxifene Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6 Polycystic Ovary Syndrome 2 Urinary Bladder Neoplasms 1 Stage I Prostate Adenocarcinoma 1 Prostatic Neoplasms 1 Osteoporosis 1 Neoplasms 1 Infertility 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Diarrhea 1 Cardiovascular Diseases 1 Carcinoma, Squamous Cell 1 Brain Neoplasms 1 Anovulation 1 Adenocarcinoma 1

Interventions

pexidartinib 1 bicalutamide 1 Raloxifene Hydrochloride 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03147196 2019-01-22

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Mayo Clinic

Phase 2 Withdrawn

Stage I Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡